Gademann G, Hartmann G H, Kraft G, Lorenz W J, Wannenmacher M
Radiologische Universitätsklinik, Abteilung Klinische Radiologie, Heidelberg.
Strahlenther Onkol. 1990 Jan;166(1):34-9.
It could be demonstrated that local tumor control is considerably improved by radiation therapy with charged particles (protons or heavier ions). The advantages of heavy ion therapy compared to conventional photon therapy techniques are due to the better physical dose distributions achievable and the radiobiological characteristics of heavy ions. However, because of the expense and complexity of heavy ion therapy it is only carried out at a few facilities throughout the world. The Radiologische Universitätsklinik (Radiological University Hospital) and the Deutsches Krebsforschungszentrum (German Cancer Research Centre, DKFZ) in Heidelberg, in collaboration with the Gesellschaft für Schwerionenforschung (Laboratory for Heavy Ion, GSI) in Darmstadt, have developed a concept to use the new heavy ion synchrotron (Schwerionen-Synchroton SIS) in Darmstadt for medical-clinical irradiations. Due to the high flexibility of the SIS accelerator the medical program can be performed in addition to the planned physical experiments with minor interference only. The close geographical proximity of the three institutes involved and the accelerator which will be completed by the end of 1989 provide the unique opportunity to carry out relevant clinical, medical-physical, physical-technical, and radiobiological research in a relatively short time and, compared to similar projects in other countries, at low cost.
可以证明，使用带电粒子（质子或重离子）进行放射治疗可显著改善局部肿瘤控制。与传统光子治疗技术相比，重离子治疗的优势在于可实现更好的物理剂量分布以及重离子的放射生物学特性。然而，由于重离子治疗的费用高昂且操作复杂，全世界只有少数机构开展此项治疗。海德堡的放射学大学医院（Radiologische Universitätsklinik）和德国癌症研究中心（Deutsches Krebsforschungszentrum，DKFZ）与达姆施塔特的重离子研究协会（Gesellschaft für Schwerionenforschung，GSI，重离子实验室）合作，提出了一项利用达姆施塔特新的重离子同步加速器（Schwerionen-Synchroton SIS）进行医学临床照射的概念。由于SIS加速器具有高度灵活性，医疗项目在进行计划中的物理实验时，只需进行少量干扰即可同时开展。所涉及的三个机构地理位置相近，且加速器将于1989年底建成，这提供了一个独特的机会，能够在相对较短的时间内，以较低的成本开展相关的临床、医学物理、物理技术和放射生物学研究，这一点与其他国家的类似项目相比具有优势。
